Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 658 Carcinoma, Non-Small-Cell Lung 455 Prostatic Neoplasms 385 Neoplasms 378 Lung Neoplasms 261 Multiple Myeloma 249 Colorectal Neoplasms 230 Neoplasm Metastasis 212 Melanoma 201 Ovarian Neoplasms 165 Leukemia, Myeloid, Acute 162 Pancreatic Neoplasms 155 Carcinoma, Renal Cell 140 Squamous Cell Carcinoma of Head and Neck 137 Lymphoma 135 Brain Neoplasms 132 Leukemia, Lymphocytic, Chronic, B-Cell 128 Glioblastoma 126 Lymphoma, Non-Hodgkin 124 Recurrence 122 Carcinoma, Hepatocellular 119 Head and Neck Neoplasms 115 Urinary Bladder Neoplasms 111 Triple Negative Breast Neoplasms 106 Stomach Neoplasms 105 Precursor Cell Lymphoblastic Leukemia-Lymphoma 103 Uterine Cervical Neoplasms 102 Hematologic Neoplasms 99 Lymphoma, Follicular 95 Sarcoma 93

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × 1 year × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡